← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mdi Therapeutics, Inc.
Novi, MI
$3,645,392
Total funding
4
Grants
Funding over time
peak $1M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,645,392 · 4
By mechanism
R44$3,203,631 · 2
R43$441,761 · 2
Investigators at Mdi Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$1,000,618
R44 · FY2022 · HL
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$746,985
R44 · FY2019 · AR
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$746,985
R44 · FY2020 · AR
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$709,043
R44 · FY2023 · HL
Preclinical development of a first in class therapeutic for treating idiopathic pulmonary fibrosis$225,000
R43 · FY2019 · HL
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$216,761
R43 · FY2018 · AR